Holen Sie sich die Stockscreener-App
3.44
3.61%
0.12
Schlusskurs vom Vortag:
$3.32
Offen:
$3.36
24-Stunden-Volumen:
33,333
Relative Volume:
0.67
Marktkapitalisierung:
$18.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-1.1279
EPS:
-3.05
Netto-Cashflow:
$-11.88M
1W Leistung:
+10.42%
1M Leistung:
+6.50%
6M Leistung:
-26.65%
1J Leistung:
-40.89%
1-Tages-Spanne:
$3.30
$3.60
1-Wochen-Bereich:
$3.10
$3.60
52-Wochen-Spanne:
$2.6838
$6.1683
Lipocine Inc Stock (LPCN) Company Profile
Firmenname
Lipocine Inc
Sektor
Branche
Telefon
801 994 7383
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Vergleichen Sie LPCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.44 | 17.76M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-11 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
| 2015-06-23 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
What analysts say about Lipocine Inc. stockHigh-impact stock picks - PrintWeekIndia
What drives Lipocine Inc. stock priceUnstoppable investment returns - Autocar Professional
How Lipocine Inc. stock performs during market volatilityDaily Stock Radar - Newser
Is Lipocine Inc. a good long term investmentFree Wealth Planning Blueprint - Autocar Professional
Lipocine Inc. Stock Analysis and ForecastSpectacular growth rates - jammulinksnews.com
What makes Lipocine Inc. stock price move sharplyTrade With Low Risk Exposure - beatles.ru
Why Lipocine Inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
Lipocine stock maintains Buy rating at H.C. Wainwright on PPD treatment potential - Investing.com Australia
Lipocine stock maintains Buy rating at H.C. Wainwright as Phase 3 trial begins - Investing.com
First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial - Patient Care Online
LPCN Begins Pivotal Phase 3 Trial for Postpartum Depression Treatment | LPCN Stock News - GuruFocus
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression - Financial Times
Lipocine to Host R&D Event on July 9 - TipRanks
HC Wainwright Estimates Lipocine’s Q1 Earnings (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright - Defense World
LPCN Stock Maintains 'Buy' Rating with $8.00 Price Target | LPCN Stock News - GuruFocus
Lipocine partner files for Canadian approval of oral TRT drug By Investing.com - Investing.com South Africa
Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq
LPCN: Lipocine's TRT Submission in Canada Marks Key Milestone | - GuruFocus
Finanzdaten der Lipocine Inc-Aktie (LPCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):